Product Images Lacosamide

This is a medication label for Lacosamide Tablets in 200mg strength. The label contains instructions for the pharmacist to refer to the accompanying Medication Guide and the recommended storage temperature. There is also a National Drug Code (NDC) number provided, which is important for identifying the product. However, there is unclear and inconsistent information provided regarding dosage and quantity of tablets per container.*

This is a medication label for Lacosamide Tablets, USP. Each tablet contains 100mg Lacosamide, and the label includes dosage information, storage instructions, and the manufacturer's information. The size of the tablet is given as 45 x 20 mm (LXH), and it has to be stored between 20°C to 25°C. There is also a note to pharmacists to provide the Medication Guide to each patient. However, there is no useful description available from the given text as it mostly consists of technical details, dosage, and storage instructions.*

Each tablet of Lacosamide contains 150mg of the medicine. The usual dosage should be obtained from the package insert. The tablets should be stored between 20°C to 25°C (68°F to 77°F) with excursions allowed between 15°C to 30°C (59°F to 86°F). The tablets are manufactured by Alkem Laboratories Ltd in India and distributed by Ascend Laboratories in Parsippany, NJ 07054. The medication guide should be provided to each patient by the pharmacist. This information is for the use of pharmacists and medical professionals only.*

This is a medication description for Lacosamide Tablets, USP. Each tablet contains 50 mg of Lacosamide. The usual dosage is not mentioned and needs to be referred to the package insert for dosage information. The tablets should be stored at a temperature between 20°C to 25°C, and excursions are permitted between 15°C to 30°C. The tablets are manufactured by Abem Laboratories Ltd, India, and distributed by Ascend Laboratories, based in NJ, USA. The label provides the NDC number (67877-733-60), capacity (60 tablets), and attention pharmacist note.*

The text provides a figure of Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose. The figure shows the percent reduction in seizure frequency for different doses of medication. There are four studies represented in the figure. The graph shows that higher doses of medication result in a greater reduction in seizure frequency. There are also statistically significant differences in reduction compared to the placebo.*

This is a chart showing the proportion of patients with responder rates for Lacosamide and placebo groups in Studies 2, 3, and 4. The chart illustrates the percentage of patients in each category, ranging from 0% to 100%, and indicates the different Lacosamide doses taken by patients.*